COVID-19 clinical trial launches
The University of Minnesota is launching a clinical trial on a post-exposure treatment for coronavirus COVID-19 disease.
This trial is testing hydroxychloroquine, an FDA-approved medicine for the prevention and treatment of malaria, available since the 1950s and known as Plaquenil(R). Recent work shows that hydroxychloroquine is active in a laboratory setting against the novel SAS-CoV2 virus, and the trial is designed to see if it translates into benefits for people.
The trial seeks to enroll up to 1,500 people who have had household contact or those who are healthcare workers who have been exposed to someone with known COVID-19 disease within the past three days and who presently are not ill. The trial is national in scope.